TIF News (IT)

“Although thalassemia has always been endemic in Europe, especially in southern European countries such as Cyprus, Greece and Italy, the disease now knows no borders and constitutes an increasing health,…

The article discusses how the COVID-19 pandemic has magnified challenges in thalassaemia care worldwide and underscores TIF’s activities throughout the coronavirus outbreak in support of patients with haemoglobinopathies. Hematology Advisor…

During this last fortnight, experts have scrambled to gain an understanding of the new heavily mutated variant, what kind of symptoms and illness it can cause, and whether it undermines…

FerriSmart is an AI-driven system for automated real-time measurement of liver-iron concentrate (LIC) in patients, using non-invasive MRI-based technology. Under the Letter of Agreement, TIF will engage with National Thalassaemia…

Expected Outcomes An understanding of the strategic vision and goals for blood safety and the protection of the blood supply, especially in low-income settings; A better understanding of the key…

 

In the aftermath of the withdrawal of Zynteglo, the first gene therapy for patients with β-thalassaemia, from Europe, TIF´s Executive Director, Dr Androulla Eleftheriou, reflects on the viability of the…